Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes

Leukemia Research

Volumn 37, Issue 3, 2013, Pages 327-332

  Hartmann, Julia ^a,b   Braulke, Friederike ^a   Sinzig, Ursula ^a   Wulf, Gerald ^a   Maas, Jens Holger ^a   Konietschke, Frank ^a   Haase, Detlef ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Klinikum Brandenburg   (Germany)

Author keywords

BFU E; CFU GM; Chelation therapy; Colony forming assays; Iron overload; Proliferation capacity

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

ADULT; AGED; ARTICLE; BURST FORMING UNIT E; CELL PROLIFERATION; CHELATION THERAPY; COLONY FORMATION; COLONY FORMING UNIT GM; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; ERYTHROID PRECURSOR CELL; FEMALE; FERRITIN BLOOD LEVEL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BENZOATES; CELL COUNT; CELL PROLIFERATION; COHORT STUDIES; ERYTHROID PRECURSOR CELLS; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TRIAZOLES;

EID: 84872930192     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.11.005     Document Type: Article

References (27)

1. Silverman L.R. Neoplasms of the hematopoietic system: myelodysplastic syndrome. Cancer medicine 2000, 1931-1946. BC Decker, Hamilton, Canada. J. Holland, E.I. Frei, R.J. Bast (Eds.).
2. Fenaux P. Myelodysplastic syndromes: from pathogenesis and prognosis to treatment. Semin Hematol 2004, 41(2 (Suppl. 4)):6-12.
3. Janssen J.W., Buschle M., Layton M., Drexler H.G., Lyons J., van den Berghe H., et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood 1989, 73(1):248-254.
4. Haase D., Feuring-Buske M., Schäfer C., Schoch C., Troff C., Gahn B., et al. Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117. Leukemia 1997, 11:674-679.
5. Hellstrom-Lindberg E. Managment of anemia associated with myelodysplastic syndrome. Semin Hematol 2005, 42(2 (Suppl. 1)):S10-S13.
6. Brechignac S., Hellstrom-Lindberg E., Bowen D.T., DeWitte T.M., Cazzola M., Fenaux P. Quality of life and economic impact of red blood cell (RBC) transfusions on patients with myelodysplastic syndromes (MDS). Blood 2004, 104:4716.
7. Porter J.B. Practical management of iron overload. Br J Haematol 2001, 115(2):239-252.
8. Bennett J.M. MDS Foundation's Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008, 83(11):858-861.
9. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23(30):7594-7603.
10. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25(23):3503-3510.
11. Leitch H.A. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007, 31(Suppl. 3):S7-S9.
12. Rose C., Brechignac S., Vassilief D., Pascal L., Stamatoullas A., Guerci-Bresler A., et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients?. A multicenter study by the GFM. Leuk Res 2010, 34:864-870.
13. Fox F., Kuendgen A., Nachtkamp K., Strupp C., Haas R., Germing U., et al. Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only. Blood 2009, 114:1747. [abstract].
14. Jensen P.D., Heickendorff L., Pedersen B., Bendix-Hansen K., Jensen F.T., Christensen T., et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996, 94(2):288-299.
15. Messa E., Cilloni D., Messa F., Arruga F., Roetto A., Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008, 120(2):70-74.
16. Gattermann N., Finelli C., Della Porta M., Fenaux P., ganser A., Guerci-Bresler A., et al. On behalf of the EPIC study investors. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res 2010, 34:1143-1150.
17. Oehler L., Geissler K., Hinterberger W. Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies. Wien Klin Wochenschr 2003, 115(13-14):537-546.
18. Nissen-Druey C., Tichelli A., Meyer-Monard S. Human hematopoietic colonies in health and disease. Acta Haematol 2005, 113(1):5-96.
19. Juvonen E., Aimolahti A., Volin L., Ruutu T. The prognostic value of in vitro cultures of erythroid and megakaryocyte progenitors in myelodysplastic syndromes. Leuk Res 1999, 23(10):889-894.
20. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17(12):3835-3849.
21. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplstic syndromes. Blood 1997, 89(6):2079-2088.
22. Vehmeyer K., Haase D., Alves F. Increased peripheral stem cell pool in MDS: an indication of disease progression?. Leuk Res 2001, 25(11):955-959.
23. Bernimoulin M., Stern M., Tichelli A., Jotterand M., Gratwohl A., Nissen C. Leukemic cluster growth in culture is an independent risk factor for acute myeloid leukemia and short survival in patients with myelodysplastic syndrome. Acta Haematol 2008, 119(4):226-235.
24. Cazzola M., Della Porta M.G., Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology American Society of Hematology Education Program 2008, 166-175.
25. Ramm G.A., Ruddell R.G. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin Liver Dis 2005, 25(4):433-449.
26. Pootrakul P., Breuer W., Sametband M., Sirankapracha P., Hershko C., Cabantchik Z.I. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 2004, 104(5):1504-1510.
27. Okabe H., Suzuki T., Omori T., Mori M., Uehara E., Hatano K., et al. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome. Rinsho Ketsueki 2009, 50(11):1626-1629.